Investors Are Gobbling Up Shares of These 10 Firms

8. Viking Therapeutics, Inc. (NASDAQ:VKTX)

Viking Therapeutics grew its share prices by 5.69 percent on Tuesday to finish at $29.14 apiece as investors loaded up positions while waiting for fresh catalysts from the series of global conferences that it is participating in this month.

At present, investors are expecting updates and developments from the three-day 46th Annual Goldman Sachs Global Healthcare Conference in Florida on June 9 to 11.

It is also set to participate in a one-on-one meeting at the Scotiabank Third Annual Healthcare Canadian Investor Day on June 17.

In April this year, Viking Therapeutics, Inc. (NASDAQ:VKTX) soared following news that its competitor, Pfizer Inc., discontinued the development of its oral obesity medication, danuglipron, amid safety concerns.

According to PFE, the decision came after a patient experienced a potential liver injury linked to the drug.

The scrapped plans, however, spelled good news for Viking Therapeutics, Inc. (NASDAQ:VKTX), which is similarly underway with the development of an oral weight loss candidate called VK2735, with Pfizer Inc. now out of the competition.